Skip to main content
. 2022 Dec 23;3(1):204–215. doi: 10.1021/jacsau.2c00592

Figure 1.

Figure 1

Therapeutically targeting Siglec-8. (A) Schematic representation of the interaction mode of Siglec-8 with 2C4 mAb and liposomes coated with NSANeu5Ac glycomimetic on the surface of immune cells. Siglec-8 is a single-pass transmembrane protein with the ECD composed of one V-type followed by two C2-type Ig domains. The intracellular tail contains ITIM and ITSM for signaling. (B) Chemical structures of three naturally occurring trisaccharides 3′SLN and 6′S–3′SLN and the synthetized glycomimetic NSANeu5Ac. Monosaccharide symbols are indicated.